Clinical outcomes after heterogeneous overlap stenting with drug-eluting Stents and bare-metal stents for de novo coronary artery narrowings

被引:10
作者
Aoki, Jiro [1 ,2 ]
Kirtane, Ajay J. [1 ,2 ]
Dangas, George D. [1 ,2 ]
Lansky, Alexandra J. [1 ,2 ]
Morales, Andy [1 ,2 ]
Kimura, Masashi [1 ,2 ]
Kim, Young-Hak [1 ,2 ]
Moussa, Issam [1 ,2 ]
Weisz, Giora [1 ,2 ]
Kreps, Edward M. [1 ,2 ]
Collins, Michael [1 ,2 ]
Frankin-Bond, Theresa [1 ,2 ]
Stone, Gregg W. [1 ,2 ]
Moses, Jeffrey W. [1 ,2 ]
Leon, Martin B. [1 ,2 ]
Mehran, Roxana [1 ,2 ]
机构
[1] Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, New York, NY 10027 USA
[2] Cardiovasc Res Fdn, New York, NY USA
关键词
D O I
10.1016/j.amjcard.2007.07.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When it is difficult to deliver multiple drug-eluting stents (DES) or when size constraints limit DES implantation, bare-metal stents (BMS) may be implanted contiguous to DES. However, the clinical outcomes after overlapping DES and BMS implantation are not known. From September 2004 to June 2006, 4,872 consecutive patients who underwent percutaneous coronary intervention consented to be enrolled in a prospective registry. Of these patients, 44 (0.9%) with de novo lesions were treated with DES and BMS overlap stenting. All patients were followed to 12 months for the assessment of clinical outcomes. The average implanted stent diameter was 2.68 +/- 0.30 mm for DES and 2.35 +/- 0.38 mm for BMS. Overlapping BMS were implanted distal to DES in all but 1 case. One patient (2.3%) experienced acute stent thrombosis and died 2 days after the Procedure. No other patient died or had a myocardial infarction during 12 months. The target vessel revascularization rate at 12 months, however, was 31.8%, mainly driven by diffuse in-stent restenosis in the BMS segments. In conclusion, the incidence of DES and BMS overlap stenting is rare in daily practice, but this procedure is associated with a high rate of target vessel revascularization. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 62
页数:5
相关论文
共 16 条
[1]   Strut position, blood flow, and drug deposition - Implications for single and overlapping drug-eluting stents [J].
Balakrishnan, B ;
Tzafriri, AR ;
Seifert, P ;
Groothuis, A ;
Rogers, C ;
Edelman, ER .
CIRCULATION, 2005, 111 (22) :2958-2965
[2]   Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation [J].
Biondi-Zoccai, GGL ;
Agostoni, P ;
Sangiorgi, GM ;
Airoldi, F ;
Cosgrave, J ;
Chieffo, A ;
Barbagallo, R ;
Tamburino, C ;
Vittori, G ;
Falchetti, E ;
Margheri, M ;
Briguori, C ;
Remigi, E ;
Iakovou, I ;
Colombo, A .
EUROPEAN HEART JOURNAL, 2006, 27 (05) :540-546
[3]   Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents [J].
Burzotta, Francesco ;
Siviglia, Massimo ;
Altamura, Luca ;
Trani, Carlo ;
Leone, Antonio Maria ;
Romagnoli, Enrico ;
Mazzari, Mario Attilio ;
Mongiardo, Rocco ;
Niccoli, Giampaolo ;
Brancati, Marta ;
Biondi-Zoccai, Giuseppe ;
Rebuzzi, Antonio Giuseppe ;
Schiavoni, Giovanni ;
Crea, Filippo .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (03) :364-368
[4]   Comparison of clinical outcomes of overlapping sirolimus- versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention [J].
Chu, William W. ;
Kuchulakanti, Pramod K. ;
Torguson, Rebecca ;
Wang, Betty ;
Clavijo, Leonardo C. ;
Suddath, William O. ;
Pichard, Augusto D. ;
Satler, Lowell F. ;
Kent, Kenneth M. ;
Waksman, Ron .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (12) :1563-1566
[5]   CORONARY MORPHOLOGICAL AND CLINICAL DETERMINANTS OF PROCEDURAL OUTCOME WITH ANGIOPLASTY FOR MULTIVESSEL CORONARY-DISEASE - IMPLICATIONS FOR PATIENT SELECTION [J].
ELLIS, SG ;
VANDORMAEL, MG ;
COWLEY, MJ ;
DISCIASCIO, G ;
DELIGONUL, U ;
TOPOL, EJ ;
BULLE, TM .
CIRCULATION, 1990, 82 (04) :1193-1202
[6]   Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease - A randomized controlled trial [J].
Kandzari, David E. ;
Leon, Martin B. ;
Popma, Jeffrey J. ;
Fitzgerald, Peter J. ;
O'Shaughnessy, Charles ;
Ball, Michael W. ;
Turco, Mark ;
Applegate, Robert J. ;
Gurbel, Paul A. ;
Midei, Mark G. ;
Badre, Sejal S. ;
Mauri, Laura ;
Thompson, Kweli P. ;
LeNarz, LeRoy A. ;
Kuntz, Richard E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (12) :2440-2447
[7]   Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents - Pooled analysis of five clinical trials [J].
Kereiakes, Dean J. ;
Wang, Hong ;
Popma, Jeffrey J. ;
Kuntz, Richard E. ;
Donohoe, Dennis J. ;
Schofer, Joachim ;
Schampaert, Erick ;
Meier, Bernhard ;
Leon, Martin B. ;
Moses, Jeffrey W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (01) :21-31
[8]   Treatment of very small vessels with 2.25-mm diameter Sirolimus-Eluting stents (from the RESEARCH Registry) [J].
Lemos, PA ;
Arampatzis, CA ;
Saia, F ;
Hoye, A ;
Degertekin, M ;
Tanabe, K ;
Lee, CH ;
Cummins, P ;
Smits, PC ;
McFadden, E ;
Sianos, G ;
de Feyter, P ;
van Der Giessen, WJ ;
van Domburg, RT ;
Serruys, PW .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (05) :633-636
[9]   Drug-eluting stent thrombosis -: Results from a pooled analysis including 10 randomized studies [J].
Moreno, R ;
Fernández, C ;
Hernández, R ;
Alfonso, F ;
Angiolillo, DJ ;
Sabaté, M ;
Escaned, J ;
Bañuelos, C ;
Fernández-Ortiz, A ;
Macaya, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (06) :954-959
[10]   Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial [J].
Moses, Jeffrey W. ;
Nikolsky, Eugenia ;
Mehran, Roxana ;
Cambier, Patrick A. ;
Bachinsky, William B. ;
Leya, Fred ;
Kuntz, Richard E. ;
Popma, Jeffrey J. ;
Schleckser, Patricia ;
Wang, Hong ;
Cohn, Sidney A. ;
Leon, Martin B. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (11) :1455-1460